[go: up one dir, main page]

BRPI0508769A - forma de dosagem resistente a adulteração compreendendo um adsorvente e um agente adverso - Google Patents

forma de dosagem resistente a adulteração compreendendo um adsorvente e um agente adverso

Info

Publication number
BRPI0508769A
BRPI0508769A BRPI0508769-4A BRPI0508769A BRPI0508769A BR PI0508769 A BRPI0508769 A BR PI0508769A BR PI0508769 A BRPI0508769 A BR PI0508769A BR PI0508769 A BRPI0508769 A BR PI0508769A
Authority
BR
Brazil
Prior art keywords
dosage form
adsorbent
adverse agent
pharmaceutical compositions
tamper
Prior art date
Application number
BRPI0508769-4A
Other languages
English (en)
Inventor
Osvaldo Abreu
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BRPI0508769A publication Critical patent/BRPI0508769A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)

Abstract

FORMA DE DOSAGEM RESISTENTE A ADULTERAçãO COMPREENDENDO UM ADSORVENTE E UM AGENTE ADVERSO. Composições e formas dosagem farmacêuticas compreendendo um adsorvente, e um agente adverso, tal como um antagonista de opióide. Em uma configuração, pelo menos um porção do agente adverso está na superfície ou dentro da estrutura de microporos de um material adsorvente. As composições e formas de dosagem farmacêuticas, compreendendo o adsorvente e o agente adverso, são úteis para prevenir ou desestimular a adulteração, abuso, mau uso ou alteração de uma forma de dosagem contendo um agente farmaceuticamente ativo, tal como um opióide. A presente invenção também se refere a métodos para tratar um paciente com esta forma de dosagem, assim como kits contendo esta forma de dosagem com instruções para uso da forma de dosagem para tratar um paciente. A presente invenção refere-se ainda a um processo para preparar as composições e formas de dosagem farmacêuticas.
BRPI0508769-4A 2004-03-30 2005-03-23 forma de dosagem resistente a adulteração compreendendo um adsorvente e um agente adverso BRPI0508769A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55830104P 2004-03-30 2004-03-30
PCT/US2005/009734 WO2005097075A2 (en) 2004-03-30 2005-03-23 Tamper resistant dosage form comprising an adsorbent and an adverse agent

Publications (1)

Publication Number Publication Date
BRPI0508769A true BRPI0508769A (pt) 2007-08-28

Family

ID=34979862

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508769-4A BRPI0508769A (pt) 2004-03-30 2005-03-23 forma de dosagem resistente a adulteração compreendendo um adsorvente e um agente adverso

Country Status (24)

Country Link
US (3) US8298579B2 (pt)
EP (1) EP1729730B1 (pt)
JP (2) JP2007530684A (pt)
KR (2) KR100963914B1 (pt)
CN (1) CN1938004B (pt)
AT (1) ATE419836T1 (pt)
AU (1) AU2005231146B2 (pt)
BR (1) BRPI0508769A (pt)
CA (1) CA2557839C (pt)
CY (1) CY1108947T1 (pt)
DE (1) DE602005012244D1 (pt)
DK (1) DK1729730T3 (pt)
ES (1) ES2321012T3 (pt)
HR (1) HRP20090203T1 (pt)
IL (1) IL178175A (pt)
MX (1) MXPA06011122A (pt)
NO (1) NO20064924L (pt)
NZ (1) NZ549479A (pt)
PL (1) PL1729730T3 (pt)
PT (1) PT1729730E (pt)
RS (1) RS50817B (pt)
SI (1) SI1729730T1 (pt)
WO (1) WO2005097075A2 (pt)
ZA (1) ZA200607224B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030065002A1 (en) * 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CA2557839C (en) 2004-03-30 2011-05-10 Euro-Celtique S.A. Tamper resistant dosage form comprising an adsorbent and an adverse agent
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2673837C (en) * 2007-01-05 2015-11-24 Acelrx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
EP2219612A4 (en) * 2007-12-17 2013-10-30 Paladin Labs Inc FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
US8460640B2 (en) * 2008-12-12 2013-06-11 Paladin Labs, Inc. Narcotic drug formulations with decreased abuse potential
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
CN102697660B (zh) * 2012-06-04 2014-02-12 贵州景峰注射剂有限公司 一种去除微丸丸间静电的方法
US20140034885A1 (en) * 2012-08-01 2014-02-06 Acura Pharmaceuticals, Inc. Stabilization of one-pot methamphetamine synthesis systems
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
AU2014370085B2 (en) * 2013-12-23 2017-10-26 Purdue Pharma L.P. Opioid antagonist formulations
WO2015103379A1 (en) * 2013-12-31 2015-07-09 Kashiv Pharma, Llc Abuse-resistant drug formulations
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US20170050173A1 (en) * 2015-08-19 2017-02-23 The Decaf Company, Llc Programmable mip catch and release technology
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3050250A1 (en) * 2017-01-13 2018-07-19 Kashiv Biosciences, Llc Opioid agonist / antagonist combination dosage forms
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN107693361B (zh) * 2017-09-13 2024-04-26 北京化工大学 一种高效缓释纳米药物的制备装置
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
EP3610860A1 (en) 2018-08-15 2020-02-19 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Composition of carbon dioxide absorbent or adsorbent, whereby the said composition contains a polymeric coating selected from silicone rubber and cellulose
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
CN113976075B (zh) * 2021-10-19 2023-09-19 恒枫食品科技有限公司 一种脱除溶液中咖啡因用的材料及系统
WO2023072929A1 (de) 2021-10-27 2023-05-04 Rheinisch Westfälische Technische Hochschule (Rwth) Aachen Umhüllte wirkstoffformulierung zu kontrollierten in vivo-aufnahme von co2
DE102021127957A1 (de) 2021-10-27 2023-04-27 Rheinisch-Westfälische Technische Hochschule Aachen, Körperschaft des öffentlichen Rechts Umhüllte Wirkstoffformulierung zu kontrollierten in vivo-Aufnahme von CO2
DE102023130381A1 (de) 2023-11-03 2025-05-08 O11 Biomedical Gmbh Vorrichtung zum enteralen Aufnehmen von CO2, sowie dementsprechendes Set
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3642986A (en) * 1970-04-01 1972-02-15 William Arthur Welch Aspirin-charcoal compositions
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS54154515A (en) * 1978-05-24 1979-12-05 Kureha Chem Ind Co Ltd Slowly releasing drug
JPS5646807A (en) * 1979-09-27 1981-04-28 Japan Atom Energy Res Inst Production of composition of complex gradually releasing physiologically active substance
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
JPS608220A (ja) * 1983-06-28 1985-01-17 Takeda Chem Ind Ltd 難溶性結晶薬物の非晶質化方法および混合粉砕物
EP0129893B1 (en) * 1983-06-28 1991-09-04 Takeda Chemical Industries, Ltd. Ground mixture
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
US4594249A (en) * 1985-06-14 1986-06-10 21St Century Marketing, Inc. Method of altering intoxicating effects of alcohol
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
FR2677886B1 (fr) * 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
JPH068220A (ja) 1992-06-23 1994-01-18 Kubota Corp 無機質板の乾式製法における給水方法及びその装置
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
US5492692A (en) * 1993-08-17 1996-02-20 University Of Kentucky Research Foundation Coated products with potent anti-HIV and antimicrobial properties
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6007843A (en) * 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
IN183097B (pt) * 1997-03-27 1999-09-04 Rajiv Indravadan Dr Modi
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6479506B1 (en) * 1998-06-16 2002-11-12 Merck Sharp & Dohme Ltd. Triazolo-pyridine derivatives as ligands for GABA receptors
US6306132B1 (en) * 1999-06-17 2001-10-23 Vivant Medical Modular biopsy and microwave ablation needle delivery apparatus adapted to in situ assembly and method of use
FR2795326B1 (fr) 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
US6353145B1 (en) * 1999-09-24 2002-03-05 Glenda Church Charcoal poultice
DE60138706D1 (de) * 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
DE10006033B4 (de) 2000-02-10 2005-11-10 Professor Dr. Magnus von Knebel Doeberitz Chirurgische Universitätsklinik Sektion für Molekulare Diagnostik und Therapie Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen
CA2363902C (en) * 2000-12-07 2005-07-26 Warner-Lambert Company Process and system for controlled-release drug delivery
RU2003122515A (ru) * 2000-12-22 2005-01-27 Эспен Аэроджелз, Инк. (Us) Порошок аэрогеля, включающий терапевтические средства
US6827932B2 (en) * 2001-01-12 2004-12-07 Raymond Crippen Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages
JP2002310357A (ja) * 2001-04-18 2002-10-23 Toray Ind Inc 自在継手および浄水器
WO2002092059A1 (en) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030065002A1 (en) * 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DE20220910U1 (de) 2001-08-06 2004-08-05 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DK1414451T3 (da) * 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
CN1652752A (zh) * 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
ES2281851T3 (es) 2003-12-09 2007-10-01 Euro-Celtique S.A. Forma de dosis co-extruida resistente a la manipulacion conteniendo un agente activo y un agente adverso y proceso para preparar el mismo.
CA2557839C (en) 2004-03-30 2011-05-10 Euro-Celtique S.A. Tamper resistant dosage form comprising an adsorbent and an adverse agent
US20100303935A1 (en) * 2009-05-29 2010-12-02 Squires Meryl J Medicinal Composition

Also Published As

Publication number Publication date
CN1938004B (zh) 2011-12-21
JP2007530684A (ja) 2007-11-01
US9795681B2 (en) 2017-10-24
NZ549479A (en) 2010-06-25
PT1729730E (pt) 2009-04-06
AU2005231146B2 (en) 2008-12-11
US20130017255A1 (en) 2013-01-17
CN1938004A (zh) 2007-03-28
PL1729730T3 (pl) 2009-06-30
ES2321012T3 (es) 2009-06-01
AU2005231146A1 (en) 2005-10-20
KR20080095309A (ko) 2008-10-28
SI1729730T1 (sl) 2009-06-30
IL178175A0 (en) 2006-12-31
HRP20090203T1 (en) 2009-05-31
EP1729730A2 (en) 2006-12-13
WO2005097075A2 (en) 2005-10-20
KR100963914B1 (ko) 2010-06-17
RS50817B (sr) 2010-08-31
DE602005012244D1 (de) 2009-02-26
CA2557839C (en) 2011-05-10
DK1729730T3 (da) 2009-03-23
ATE419836T1 (de) 2009-01-15
IL178175A (en) 2010-05-17
US20070207089A1 (en) 2007-09-06
WO2005097075A3 (en) 2006-08-03
KR20060135043A (ko) 2006-12-28
CY1108947T1 (el) 2014-07-02
NO20064924L (no) 2006-12-21
MXPA06011122A (es) 2007-03-21
JP2011093927A (ja) 2011-05-12
EP1729730B1 (en) 2009-01-07
CA2557839A1 (en) 2005-10-20
US8298579B2 (en) 2012-10-30
KR101053558B1 (ko) 2011-08-03
ZA200607224B (en) 2008-04-30
US20140256764A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
BRPI0508769A (pt) forma de dosagem resistente a adulteração compreendendo um adsorvente e um agente adverso
BRPI0608840B8 (pt) composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
WO2007143607A3 (en) Method of treating atrophic vaginitis
WO2005055981A3 (en) Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
BR0212019A (pt) Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
MY141025A (en) Dose forms
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BRPI0710483B8 (pt) dispositivo compreendendo composições com fenilefrina, cloridrato de fenilefrina, bromidrato de fenilefrina, e misturas das mesmas e kits úteis para o tratamento de doenças respiratórias
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0406634A (pt) Uso de um anagrelìdeo, anagrelìdeo na forma de base, ou um sal farmaceuticamente aceitável do anagrelìdeo, composição farmacêutica não-oral, e dispositivo médido para administração transdérmica
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
BR0209613A (pt) Composição para tratamento de dor em um mamìfero, e, método para redução ou eliminação de probabilidade de viciamento de um analgésico em um hospedeiro
BRPI0602179A (pt) composição farmacêutica compreendendo ciclobenzaprina e aceclofenaco em combinação
ATE471375T1 (de) Vglut-spezifische dsrna-verbindungen
BRPI0510906A (pt) composição farmacêutica tópica, composição para administração tópica e seu uso
BR0204185A (pt) Uso de substâncias agonistas de canais de k+ para prevenir ou tratar danos teciduais promovidos por ácido metil-malÈnico, composição farmacêutica compreendendo substâncias agonistas, composição para o tratamento ou prevenção de danos teciduais, composição compreendendo o uso de substâncias agonistas para uso no tratamento ou prevenção de danos teciduais, bem como composições apresentáveis em quaisquer formas farmacêuticas compreendendo substância agonista para uso no tratamento ou prevenção de danos teciduais
BRPI0400359A (pt) Uso de um fucano, composição farmacêutica, e, método para preparar um medicamento capaz de reduzir sintomas associados com pelo menos uma dentre aderência, artrite, e psorìase em um paciente humano

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2260 DE 29/04/2014.

B25G Requested change of headquarter approved

Owner name: EURO-CELTIQUE S.A (LU)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2437 DE 19/09/2017 POR TER SIDO INDEVIDA.

B11T Dismissal of application maintained [chapter 11.20 patent gazette]